Statin shows promise for COPD inflammation in small trial

NCT ID NCT07549932

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed study tested whether adding a daily statin (atorvastatin 20 mg) to standard treatment for six months could reduce airway inflammation and improve lung function in 80 people with severe COPD. Researchers measured blood markers of inflammation and breathing tests. The goal was to see if this cheap, widely available drug could offer extra benefits for COPD management.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

atorvastatin (statin)

What this could lead to

If statins prove helpful, they could become a low-cost add-on treatment to reduce inflammation and slow COPD progression.

What could go wrong

This is a small, completed study with no phase designation, so results may not be conclusive. Statins also carry risks like muscle pain or liver issues.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC OBSTRUCTIVE PULMONARY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic obstructive pulmonary disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • utpatient clinic and Inpatient quarters of the Thoracic Medicine Department of Mansoura University Hospitals

    Al Mansurah, Egypt